This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Find out more here.

eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
New eMC coming June 2013...

Forum Health Products Limited

Forum Health Products Limited, Betchworth House, 57/65 Station Road, Redhill, Surrey, RH1 1DL
Telephone: +44 (0)1737 857 782
Fax: +44 (0) 1737 857701
Medical Information Direct Line: 0500 455 456
Customer Care direct line: 0500 455 456

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Summary of Product Characteristics last updated on the eMC: 19/03/2013
SPC Gaviscon Advance - Peppermint

Go to top of the page
1. Name of the medicinal product

Gaviscon Advance Peppermint Flavour

Oral Suspension.

Go to top of the page
2. Qualitative and quantitative composition

Each 10 ml dose contains sodium alginate 1000 mg and potassium hydrogen carbonate 200 mg. 1 ml contains sodium alginate 100 mg and potassium hydrogen carbonate 20.0 mg.

Each 10 ml dose is equivalent to two 5 ml measuring spoons.

For a full list of excipients, see section 6.1.

Go to top of the page
3. Pharmaceutical form

Oral suspension.

Off-white viscous suspension.

Go to top of the page
4. Clinical particulars

Go to top of the page
4.1 Therapeutic indications

Treatment of symptoms resulting from the reflux of acid, bile and pepsin into the oesophagus such as acid regurgitation, heartburn, indigestion (occurring due to the reflux of stomach contents), for instance, after gastric surgery, as a result of hiatus hernia, during pregnancy, accompanying reflux oesophagitis, including symptoms of laryngopharyngeal reflux such as hoarseness and other voice disorders, sore throats and cough. It can also be used to treat the symptoms of gastro-oesophageal reflux during concomitant treatment with or following withdrawal of acid suppressing therapy.

Go to top of the page
4.2 Posology and method of administration

Adults and children 12 years and over: 5-10 ml after meals and at bedtime (one to two 5 ml measuring spoons).

Children under 12 years: Should be given only on medical advice.

Elderly: No dose modification is required for this age group.

Go to top of the page
4.3 Contraindications

The medicinal product is contraindicated in patients with known or suspected hypersensitivity to the active substances or to any of the excipients.

Go to top of the page
4.4 Special warnings and precautions for use

Each 10 ml dose has a sodium content of 106 mg (4.6 mmol) and a potassium content of 78 mg (2.0 mmol). This should be taken into account when a highly restricted salt diet is recommended, e.g. in some cases of congestive cardiac failure and renal impairment or when taking drugs which can increase plasma potassium levels.

Each 10 ml contains 200 mg (2.0 mmol) of calcium carbonate. Care needs to be taken in treating patients with hypercalcaemia, nephrocalcinosis and recurrent calcium containing renal calculi.

There is a possibility of reduced efficacy in patients with very low levels of gastric acid.

Treatment of children younger than 12 years of age is not generally recommended, except on medical advice.

If symptoms do not improve after seven days, the clinical situation should be reviewed.

This medicinal product contains Methyl hydroxybenzoate and Propyl hydroxybenzoate, which may cause allergic reactions (possibly delayed).

Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

None known.

Go to top of the page
4.6 Pregnancy and lactation

An open, uncontrolled study in 146 pregnant women did not demonstrate any significant undesirable effects of Gaviscon Advance on the course of the pregnancy or on the health of the foetus/new-born child. Based on this and previous experience, Gaviscon Advance - Peppermint Flavour may be used during pregnancy and lactation. Nevertheless, taking into account the presence of calcium carbonate it is recommended to limit the treatment duration as much as possible.

Go to top of the page
4.7 Effects on ability to drive and use machines

Not relevant.

Go to top of the page
4.8 Undesirable effects

Very rarely (<1/10,000) patients may develop allergic manifestations such as urticaria or bronchospasm, anaphylactic or anaphylactoid reactions.

Go to top of the page
4.9 Overdose

In the event of overdose, symptomatic treatment should be given. The patient may notice abdominal distension.

Go to top of the page
5. Pharmacological properties

Go to top of the page
5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD).

ATC code: A02BX.

On ingestion the suspension reacts with gastric acid to rapidly form a raft of alginic acid gel having a near-neutral pH which floats on the stomach contents quickly and effectively impeding gastro-oesophageal reflux for up to 4 hours, and protecting the oesophagus from acid, pepsin and bile. In severe cases the raft itself may be refluxed into the oesophagus in preference to the stomach contents and exert a demulcent effect. In addition in vitro evidence has shown that the raft has a secondary action and is able to entrap bile and pepsin within its structure, further protecting the oesophagus from these gastric components.

Go to top of the page
5.2 Pharmacokinetic properties

The mechanism of action of the medicinal product is physical and does not depend on absorption into the systemic circulation.

Go to top of the page
5.3 Preclinical safety data

No preclinical findings of relevance to the prescriber have been reported.

Go to top of the page
6. Pharmaceutical particulars

Go to top of the page
6.1 List of excipients

Calcium carbonate

Carbomer 974P

Methyl parahydroxybenzoate E218

Propyl parahydroxybenzoate E216

Saccharin sodium

Peppermint flavour

Sodium hydroxide for pH adjustment

Purified water

Go to top of the page
6.2 Incompatibilities

Not applicable.

Go to top of the page
6.3 Shelf life

Shelf life: 2 years.

Shelf-life after opening: 6 months.

Go to top of the page
6.4 Special precautions for storage

Do not refrigerate.

Go to top of the page
6.5 Nature and contents of container

Amber glass bottles with moulded polypropylene cap having a tamper evident strip and lined with an expanded polyethylene wad. The bottles are enclosed in a cardboard outer containing either a measuring device (natural polypropylene) containing 5, 10, 15 and 20 ml graduations or a clear injection moulded crystal polystyrene measuring spoon with one bowl containing 2.5 ml and 5 ml measure. The pack sizes are 80, 100, 125, 140, 150, 180, 200, 250, 300, 400, 500, 560 or 600 ml suspension. Not all pack sizes may be marketed. The carton and measuring device or spoon may not be made available in all markets/pack sizes.

Go to top of the page
6.6 Special precautions for disposal and other handling

No special requirements.

Go to top of the page
7. Marketing authorisation holder

Reckitt Benckiser Healthcare (UK) Limited, Dansom Lane, Hull, HU8 7DS, United Kingdom.

Go to top of the page
8. Marketing authorisation number(s)

PL 00063/0612.

Go to top of the page
9. Date of first authorisation/renewal of the authorisation


Go to top of the page
10. Date of revision of the text


More information about this product

Link to this document from your website:

Active Ingredients/Generics